In particular, a loss-of-function mutation (R381Q) in IL-23R, which results in decreased downstream IL-17 production and reduced STAT3 activation, is protective in psoriasis and IBD17,19,21, providing the basis for IL-23R antagonism as a therapeutic approach in these diseases. Here, IL23R is linked to psoriasis.